GleamWall
中文EN

CMMB Chemomab Therapeutics Ltd.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1534248 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY35.5%
TTM EPS YoY-53.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-69.5%
ROA-58.5%
ROIC (approx.)-1,446.2%
Asset turnover—

Leverage & solvency

Liabilities / assets10.7%
Debt / equity0.00x
Current ratio9.08x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.24x
Accruals ratio13.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
Cost of revenue$2.33M$2.46M
R&D expense$5.83M$11.33M
SG&A expense$3.73M$3.41M
Operating income-$112.00M-$103.00M
Pretax income-$8.99M-$13.95M
Income tax$0$0
Net income-$8.99M-$13.95M
EBITDA-$111.93M-$102.95M
EPS (basic)0.020.04
EPS (diluted)0.020.04
Weighted avg. shares (diluted)510.23M359.05M
Balance sheet
Cash & equivalents$7.56M$6.07M
Current assets$13.43M$16.04M
PP&E, net$176,000$250,000
Total assets$13.81M$16.96M
Current liabilities$1.48M$3.22M
Total liabilities$1.48M$3.43M
Shareholders' equity$12.33M$13.54M
Shares outstanding—377.13M
Cash flow statement
Operating cash flow-$11.13M-$15.39M
Capital expenditure$3,000$0
Free cash flow-$11.13M-$15.39M
Investing cash flow$5.39M$2.30M
Financing cash flow$7.16M$9.87M
Depreciation & amortization$70,000$53,000
Stock-based compensation$623,000$617,000

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.